California-based, AI-driven healthcare solution company Syllable raised USD 40 million in Series C funding. The round took place on April 25, 2022. Growth equity firm TCV led the Series C funding for Syllable. Meanwhile, existing investors, including Oak HC/FT, Section32, and Verily, invested in the funding.
Purpose of Funding for Syllable
The recent investment from the Series C round will further improve the patient experience with intelligent voice solutions for health system call centres and medical practice offices.
Syllable intends to use the latest funding to develop further its main solution, the Syllable Patient Assistant, which meets patients where they are – on the phone, web, and via SMS. Syllable Patient Assistant greets calls within seconds and guides patients through a conversational workflow to reach the next step in their healthcare journey.
What the founder has to say
Kobus Jooste, CEO of Syllable, said, “Syllable’s automation has demonstrated our ability to modernize the healthcare contact centre and improve the patient experience. We work closely with health systems to provide intelligent, automated features with the Syllable Patient Assistant and focus on improving access to care for all patients in the U.S. We look forward to our new relationship with TCV and also continue to serve our health system partners by expanding the deployment of Syllable for patients.”
In addition, he said, “U.S. citizens and their families experience an inferior customer experience in what is the most important service they will ever need. Due to staffing issues in healthcare, healthcare contact centres have long call-hold times, rerouted or dropped calls, and dead ends, which all contribute to a frustrating patient experience and make it cumbersome to access vital care quickly. We extended the assistant to support vaccine distribution, including outbound voice, and SMS awareness and patient outreach campaigns. Syllable is dedicated to working with health systems in the U.S. to make access to care more inclusive and approachable for all Americans. Syllable works with metropolitan and rural populations of non-English speakers and patients without commercial insurance who utilize Medicare or Medicaid. Syllable’s mission is to improve the patient experience by using artificial intelligence to identify opportunities to improve the patient experience through automation.”
What the investor has to say
“Implementing truly patient-centric call centre automation and digital self-service tools is critical for health systems to serve their patients better. Syllable’s technology platform and approach are poised to do just that. We’re excited to back a company on a mission to help improve the patient experience while enabling health systems to thrive,” said TCV General Partner Matt Brennan.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover as well as what information you are looking for, in the comments section below or through our contact form!
We look forward to your feedback, and thank you for stopping by!
Next Article
